Related ICPTCNBC’s Meg Tirrel Speculates About Gilead’s New AcquisitonHow Wedbush’s Liana Moussatos Is Trading These Biopharma StocksShaken, Not Stirred: Is The ‘Biotech Bubble’ Beginning To Burst?(Seeking Alpha)Related Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platformShort-Sellers Betting Against These BiotechsSarepta Posts Narrower-than-Expected Loss in […]
By Ben LevisohnSunTrust Robinson Humphrey’s Edward Nash and team offer five biotech stocks for the next six months:
Cempra (CEMP) ($50 PT), our top pick based on near-term clinical and commercial success potential. We recently met with management and it was reiterated that the second Phase III study of solithromycin in CABP (SOLITAIRE-IV) remains on track to report top-line data by […]
Sarepta Therapeutics (NASDAQ:SRPT)After the closing bell on May 19, 2015 shares of Sarepta Therapeutics were up as much as 38% in after-hours trading after the company reported that the FDA will allow the company to file a New Drug Application — NDA — for Eteplirsen. This drug Eteplirsen helps patients with Duchenne Muscular Dystrophy — DMD — to restore dystrophin […]
View gallery.Preface: The biotech stocks considered for this review were confined to those over $10 per share that traded at least 500K shares a day based on a 90-day average.For the longest time it seemed that for every new high the S&P 500 hit, biotech stocks, as measured by the iShares Nasdaq Biotechnology Index (NASDAQ: IBB), hit two new […]
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked ;the Twittersphere for their favorite drug stocks going into next year.
What’s your favorite stock for 2015 in biotech or Pharma?
– Mark Schoenebaum (@MarkSchoenebaum) December 12, 2014What was the top pick? A 21-way tie for first place. All 21 companies got a single vote.I kid you not. As I’m writing […]
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the S&P 500 , and more than doubled the NASDAQ Composite , since 2012.This sustained move upward, though, has repeatedly […]
View gallery.Biotech stocks can provide enormous gains, but unfortunately, they can take them away just as quickly.All it takes is one FDA approval for a biotech company’s stock to soar, but an FDA setback could also cause that same stock to tank. One biotech stock suffered that outcome Monday morning.Sarepta Therapeutics Inc (NASDAQ: SRPT) provided an update on its discussions […]